Cancer Types | Cervical Cancer - NFCR

Cervical Cancer

Cervical Cancer

Cervical cancer continues to affect women of all ages worldwide. The disease often presents no symptoms in its early stages, which is why it is often referred to as one of the “silent killers.”

Key Facts

  • Most cervical cancers are caused by the human papillomavirus (HPV), a common virus that can be passed from one person to another through sexual activity.

  • With the advent of the HPV vaccine and regular Pap screening tests, most cervical cancers can now be prevented.

  • In 2021, it is estimated that 14,480 women will be diagnosed with invasive cervical cancer in the U.S. and 4,290 patients will lose their battle with the disease.

  • Although the number of new cases has been declining over the past decades in the U.S., thanks to Pap screening, cervical cancer is the third most common type of cancer for women worldwide.

Source: American Cancer Society’s Cancer Facts & Figures 2021 and National Cancer Institute’s Fact Sheet Cervical Cancer

Signs and Symptoms

A symptom is a change in the body that a person can see and/or feel. A sign is a change that the doctor sees during an examination or on a laboratory test result. If you have any of the symptoms below, it does not mean you have cancer but you should see your doctor or health care professional so that the cause can be found and treated, if needed.

  • Abnormal vaginal bleeding
  • An unusual discharge from the vagina
  • Pain during sex
  • Pain in the pelvic region
  • Swelling of the legs (ADVANCED)
  • Problems urinating or having a bowel movement
  • Blood in the urine
Source: American Cancer Society
Teal Cervical Cancer Ribbon
expected diagnoses in 2021
deaths expected in 2021
third most common cancer for women

Cervical Cancer Research

In addition to specific projects listed below, genomics research is helping us attack cervical cancer – and all types of cancer. NFCR has distinguished itself from other organizations by emphasizing long-term, transformative research and working to move people toward cancer genomics.

Paul Fisher, M.Ph., Ph.D.
Paul Fisher, M.Ph., Ph.D.
Dr. Web Cavenee
Web Cavenee, Ph.D.

Dr. Paul Fisher is developing novel therapies that deliver an immune modulator gene he discovered, IL/24, to primary and spreading tumor cells of many cancers, leaving healthy cells untouched. In models of cervical and numerous other types of cancer, IL/24 causes the tumor cells to commit ‘cell suicide’.

I/24 has other powerful anti-cancer properties including activation of the immune system to further fight cancer and sensitizing tumor cells to radiation, chemotherapy and immunotherapy. One type of IL/24 gene therapy in development by Dr. Fisher’s team also includes a gene that fluoresces (lights up) when IL/24 finds and destroys tumor cells for theranostic approach (detection and treatment-monitoring). Another therapy combines IL/24 with a patient’s own immune T cells (adoptive cell therapy) to supercharge the T cells to fight cancer more effectively. Research is advancing quickly so patients with many types of cancer may benefit from these groundbreaking therapies.

With support from NFCR, Dr. Fisher and Dr. Web Cavenee are first advancing the lL/24 therapies for the aggressive brain cancer, GBM. IL/24 gene therapy will advance soon to a Phase I clinical trial to provide GBM patients hope for a new effective treatment.

Harold F. Dvorak, M.D.
Harold F. Dvorak, M.D.

Former NFCR-supported scientist, Dr. Harold F. Dvorak, received NFCR funding for over 30 years. He discovered the vascular endothelial cell growth factor (VEGF), which plays a central role in angiogenesis—the process by which tumors recruit blood vessels to supply the nutrients they need to grow and survive. Dr. Dvorak’s breakthrough led the research community to develop inhibitors of VEGF. One anti-VEGF targeted cancer therapy, Avastin®, has treated over 1.5 million patients with various types of primary and metastatic cancers. In 2014, this anti-VEGF antibody combined with chemotherapy was approved by the FDA to treat patients with persistent, recurrent or metastatic cervical cancer.

Related Content

NEW Cervical Cancer Screening Guidelines

Buried amongst the pandemic commotion was American Cancer Society’s newest cervical cancer screening guidelines. Cervical cancer affects women of all ages worldwide and is often dubbed ‘the silent killer’ as it presents with no symptoms in the early stages. Luckily there is an effective screening method to help reduce the number of late-stage diagnoses. Though the latest guidelines were announced in July 2020, Cervical Cancer Awareness Month is an excellent time to remind people of these latest changes. Who should get screened? People with a cervix aged from 25 years to 65 years should get screened. People over the age of 65 who have had regular screening in the past 10 years with normal results and no history of abnormal cells in the cervix (nor a more serious diagnosis in the part 25 years) should stop cervical screening. Once stopped, it should not be started again. People who have had a total hysterectomy (removal of the uterus and cervix) should stop screening unless the hysterectomy was done as a treatment for cervical cancer or serious pre-cancer. However, those who have had a supra-cervical hysterectomy (hysterectomy without the removal of the cervix) should continue cervical cancer screening in adherence to the guidelines. Cervical cancer screening should continue even after having children and after being vaccinated against the human papilloma virus (HPV). What is the recommended way to get screened? The preferred screening is to get a primary HPV test every five years. A primary HPV test is an HPV test that is done by itself for screening. The US Food and Drug Administration (FDA) has approved certain tests to be primary tests, however these may not be widely available in the United States yet. For those who do not have access to a primary HPV test, it is recommended to either undergo a co-test every five years, which combines an HPV test with a pap test OR schedule a pap test alone every three years. Why should I get screened? Being screened for cervical cancer allows medical professionals to identify pre-cancers that are likely to progress to cancer and remove them before they are able to progress. Screening also allows medical teams to identify cervical cancer at an early stage, when it is mostly easily treated. What happens if the results come back abnormal? Abnormal results are frightening, but it’s important to be prepared. If results come back abnormal, discuss the results carefully with the healthcare team. It is important to understand what the results mean and know the course of action for what is to come. The healthcare team will discuss follow-up schedules, tests, and treatment options depending on the specific risk of developing cervical cancer. However, if any issues or concerns arise between screenings or appointments, see a doctor right away. Symptoms of cervical cancer include unusual bleeding, unusual discharge from the vagina, or pain during sex and, if experiencing any of these symptoms, schedule a screening as soon as possible. It’s important to remember that you should consult your doctor on all of your health questions and prior to making important decisions regarding your healthcare. Additional Reads You […]

How to Protect Yourself from Cervical Cancer

Five Facts Every Woman Should Know About Gynecologic Cancer